A randomized controlled trial of sirolimus-based immunosuppression versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2011
INTERVENTION: Control group:mTOR‐inhibitor‐free immunosuppression;Test group:sirolimus‐based immunosuppression; CONDITION: Hepatocellular carcinoma PRIMARY OUTCOME: incidence of adverse events(AE);rate of HCC recurrency; SECONDARY OUTCOME: recurrence‐free survival; INCLUSION CRITERIA: 1. Patients with hepatocellular carcinoma (HCC) underwent liver transplantation; 2. Age over 18 years and under 65 years; 3. Tumors without major vascular invasion or exhapatic metastasis before LT; 4. Voluntary and signed informed consent.
Epistemonikos ID: 371de517fe9f854137635f90b25eec3cde6adcb9
First added on: Aug 22, 2024